Affiliation:
1. Centro Hospitalar Universitário de São João Porto Portugal
2. ViiV Healthcare Algés Portugal
3. ViiV Healthcare Durham North Carolina USA
Abstract
AbstractObjectivesPeople living with HIV face several challenges as they age, including the potential for polypharmacy and increased susceptibility to drug‐related adverse effects. Thus, effective and well‐tolerated regimens with minimal or no drug interactions would be useful in this population. We present real‐world effectiveness and safety data for individuals aged >50 years who achieved virological suppression (HIV‐1 RNA <50 copies/mL) and switched to dolutegravir/lamivudine (DTG/3TC).MethodsThis retrospective, observational, single‐centre study conducted in Portugal included individuals aged >50 years who switched to DTG/3TC while virologically suppressed and had ≥12 months of follow‐up. Proportions of individuals maintaining virological suppression were described at 12 months; CD4+ cell counts were described at baseline and 12 months. Descriptive subgroup analyses were performed based on age, sex assigned at birth, and availability of historical genotypic resistance results.ResultsOverall, 538 individuals aged >50 years were included (74% male; mean age, 62 years; mean time on previous therapy, 160 months). High proportions (intention‐to‐treat population, 97%; on‐treatment population, 98%) of individuals who switched to DTG/3TC maintained virological suppression through 12 months of follow‐up. CD4+ cell counts remained stable (mean baseline: 727 cells/mm3 [range 94–2371]; mean month 12: 742 cells/mm3 [range 99–2659]). No individuals experienced virological failure. Nine (2%) individuals discontinued DTG/3TC for non–treatment‐related reasons. Proportions with virological suppression at month 12 were similar between on‐treatment subgroups by age, sex assigned at birth, and historical genotypic resistance results availability.ConclusionsDTG/3TC demonstrated robust effectiveness and a good safety profile in individuals aged >50 years with virological suppression in Portugal.
Reference15 articles.
1. Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.https://clinicalinfo.hiv.gov/en/guidelines/adult‐and‐adolescent‐arv. Accessed February 27 2024
2. AIDSinfo.Global data on HIV epidemiology and response: indicator registry.https://aidsinfo.unaids.org/. Accessed January 2 2024
3. Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
4. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
5. European AIDS Clinical Society.Guidelines version 12.0 October 2023.https://www.eacsociety.org/media/guidelines-12.0.pdf. Accessed October 18 2023